Terri Steele, MD
Psychiatry · Birmingham, ALNPI 1730108192
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 379 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.
Across 379 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$951
- Johnson & Johnson$765
- Teva Pharmaceuticals USA, Inc.$653
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$569
- Alkermes, Inc.$555
- plus $2K from 18 others
What the payments were for
- Food & beverage$7,06299%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 58 | $1,216 |
| AbbVie(2 entities) | 74 | $951 |
| Johnson & Johnson | 40 | $765 |
| Teva Pharmaceuticals USA, Inc. | 40 | $653 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $569 |
| Alkermes, Inc. | 29 | $555 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $478 |
| Lundbeck LLC | 19 | $418 |
| Neurocrine Biosciences, Inc. | 21 | $340 |
| Vanda Pharmaceuticals Inc. | 11 | $277 |
| Supernus Pharmaceuticals, Inc. | 12 | $230 |
| Axsome Therapeutics, Inc. | 8 | $225 |
| Indivior Inc. | 7 | $108 |
| Bausch Health US, LLC | 4 | $88 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $45 |
| Almatica Pharma LLC | 2 | $43 |
| Tris Pharma Inc | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Neuronetics, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Orexo US, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $14 |
How this compares
$7,164 in reported general payments places this provider in the 85th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 11 | $155,581 |
| RexultiBrexpiprazole | 12 | $17,756 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,381 |
| Duloxetine Hcl | 132 | $3,356 |
| Aripiprazole | 60 | $3,024 |
| Bupropion XlBupropion Hcl | 107 | $2,641 |
| Chlorpromazine Hcl | 15 | $2,203 |
| Buspirone Hcl | 92 | $1,432 |
| Alprazolam OdtAlprazolam | 12 | $1,403 |
| Trazodone Hcl | 115 | $1,221 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 52 | $1,080 |
| Lurasidone Hcl | 31 | $1,032 |
| Paliperidone ErPaliperidone | 13 | $980 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $795 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 26 | $754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $653 | $155,58111 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,216 | $17,75612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $478 | $7,38116 claims |
| Almatica Pharma LLCSertraline Hcl | $43 | $35849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Birmingham
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Richard SheltonBirmingham$79K
- Melissa KarrhBirmingham$51K
- Matthew MacalusoBirmingham$49K
- Santosh PillaiBirmingham$28K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.